{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:34:39Z","timestamp":1790872479098,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,8,1]]},"abstract":"<jats:p> Purpose: The objectives of this prospective randomized study of consolidation therapy were to evaluate recurrence-free survival (RFS), overall survival (OS), and the morbidity of intraperitoneal (IP) chromic phosphate suspension (<jats:sup>32<\/jats:sup>P) therapy in patients with stage III epithelial ovarian carcinoma who have no detectable evidence of disease at the second-look laparotomy (SLL) procedure after primary chemotherapy. <\/jats:p><jats:p> Patients and Methods: In a multi-institution clinical cooperative trial, 202 eligible patients with a negative SLL were randomly selected to receive either 15 mCi IP <jats:sup>32<\/jats:sup>P (n = 104) or no further therapy (NFT; n = 98). <\/jats:p><jats:p> Results: With a median follow-up of 63 months in living patients, 68 patients in the IP <jats:sup>32<\/jats:sup>P group (65%) and 63 patients in the NFT group (64%) have developed tumor recurrence. The relative risk of recurrence is 0.90 (IP <jats:sup>32<\/jats:sup>P to NFT) (90% confidence interval [CI], 0.68 to 1.19). The 5-year RFS rate is 42% and 36% for the IP <jats:sup>32<\/jats:sup>P and NFT groups, respectively; the difference is not statistically significant (log-rank test, P = .27). There was no statistically significant difference in OS (P = .19). The relative risk of death is 0.85 (IP <jats:sup>32<\/jats:sup>P to NFT) (90% CI, 0.62 to 1.16). Sixteen patients (8%) experienced grade 3 or 4 adverse effects, with eight in each respective group. <\/jats:p><jats:p> Conclusion: Intraperitoneal chromic phosphate did not decrease the risk of relapse or improve survival for patients with stage III epithelial ovarian cancer after a negative SLL. Despite complete pathologic remission at SLL after initial surgery and platinum-based chemotherapy, 61% of stage III ovarian cancer patients had tumor recurrence within 5 years of negative SLL. This indicates a need for more effective initial therapy and further studies of consolidation therapy. <\/jats:p>","DOI":"10.1200\/jco.2003.11.018","type":"journal-article","created":{"date-parts":[[2003,7,28]],"date-time":"2003-07-28T19:31:30Z","timestamp":1059420690000},"page":"2849-2855","source":"Crossref","is-referenced-by-count":69,"title":["Intraperitoneal Radioactive Phosphorus (<sup>32<\/sup>P) Versus Observation After Negative Second-Look Laparotomy for Stage III Ovarian Carcinoma: A Randomized Trial of the Gynecologic Oncology Group"],"prefix":"10.1200","volume":"21","author":[{"given":"Mahesh A.","family":"Varia","sequence":"first","affiliation":[{"name":"From the Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC; Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Department of Pathology, University of Iowa Hospitals, Iowa City, IA; Duke University Medical Center, Durham, NC; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick B.","family":"Stehman","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC; Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Department of Pathology, University of Iowa Hospitals, Iowa City, IA; Duke University Medical Center, Durham, NC; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian N.","family":"Bundy","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC; Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Department of Pathology, University of Iowa Hospitals, Iowa City, IA; Duke University Medical Center, Durham, NC; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo Ann","family":"Benda","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC; Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Department of Pathology, University of Iowa Hospitals, Iowa City, IA; Duke University Medical Center, Durham, NC; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Clarke-Pearson","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC; Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Department of Pathology, University of Iowa Hospitals, Iowa City, IA; Duke University Medical Center, Durham, NC; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Alvarez","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC; Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Department of Pathology, University of Iowa Hospitals, Iowa City, IA; Duke University Medical Center, Durham, NC; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry J.","family":"Long","sequence":"additional","affiliation":[{"name":"From the Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC; Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN; Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; Department of Pathology, University of Iowa Hospitals, Iowa City, IA; Duke University Medical Center, Durham, NC; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197609)38:3<1438::AID-CNCR2820380351>3.0.CO;2-2"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(16)32778-8"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(81)90016-0"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(82)90101-9"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(16)32428-0"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197707282970402"},{"key":"R7","unstructured":"Kapadia SB, Krause JR: Ovarian carcinoma terminating in lymphocytic leukemia following alkylating agent therapy. Cancer 297:177,1978\u2013181,"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(85)80041-7"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850301)55:5<1129::AID-CNCR2820550531>3.0.CO;2-O"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(91)90333-Z"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<128::AID-CNCR21>3.0.CO;2-6"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880301)61:5<919::AID-CNCR2820610511>3.0.CO;2-P"},{"key":"R13","unstructured":"Buchsbaum HJ, Keetel WC: Radioisotopes in treatment of stage I ovarian cancer. NCI Monogr 42:127,1975\u2013128,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1097\/00006254-197909000-00028"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199004123221501"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(89)90631-8"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.165.1.3628782"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(87)90131-1"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890615)63:12<2434::AID-CNCR2820631211>3.0.CO;2-B"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.457"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(81)90007-2"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.2307\/2531201"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R24","unstructured":"Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemo Rep 50:163,1966\u2013170,"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Cox DR: Regression model and Life Tables (with discussion). J R Stat Soc 34:(B):187,1972,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(16)34437-4"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197812)42:6<2563::AID-CNCR2820420609>3.0.CO;2-D"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920201)69:3<741::AID-CNCR2820690322>3.0.CO;2-G"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930401)71:7<2250::AID-CNCR2820710715>3.0.CO;2-#"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Walton LA, Yadusky A, Rubinstein L: Intraperitoneal radioactive phosphate in early ovarian carcinoma. An analysis of complications. Int J Radiat Oncol Biol Phys 20:939,1997\u2013944,","DOI":"10.1016\/0360-3016(91)90189-B"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(85)90266-5"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1016\/0090-8258(92)90298-W"},{"key":"R35","unstructured":"Ozols RF, Bundy BN, Fowler J, et al: Randomized phase III study of cisplatin (Cis)\/paclitaxel (PAC) versus carboplatin (CARBO)\/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group Trial (GOG 158). Proc Am Soc Clin Oncol 18:356a,1999,  (abstr 1373)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.11.018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:31:30Z","timestamp":1653510690000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.11.018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,1]]},"references-count":33,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2003,8,1]]}},"alternative-id":["10.1200\/JCO.2003.11.018"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.11.018","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,1]]}}}